- Adults with type 2 diabetes (T2D) who switch from first-generation to second-generation basal insulin analogs achieve similar reductions in HbA1c.
Why this matters
- This study provides findings that support results from randomized clinical trials and reflect effectiveness in real‐world clinical practice, say researchers.
- Researchers studied the electronic medical records of adult patients (n=3184; age ≥18 years) who switched from insulin glargine 100 units/mL (Gla‐100) or insulin detemir (IDet) to insulin glargine 300 units/mL (Gla‐300) or insulin degludec (IDeg).
- Funding: Sanofi.
- Both Gla-300 and IDeg switchers had similar mean decreases in HbA1c and HbA1c goal (
- No significant differences in hypoglycemia incidence and event rate were found at follow-up for Gla-300 vs IDeg after adjusting for baseline hypoglycemia.
- The treatment effect on hypoglycemia could have been underestimated because self‐monitored blood glucose and continuous blood glucose monitoring data were not available.
- Follow up was ≤6 months.